SCHEMBL16201339

SCHEMBL16201339

CCCN(C)Cc1c[nH]nc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 2/20 0.38
PRMT8 Q9NR22 2/20 0.38
PRMT1 Q99873 2/20 0.38
PRMT3 O60678 1/20 0.38
CARM1 Q86X55 1/20 0.38
SCN9A Q15858 3/20 0.36
DRD2 P14416 1/20 0.35
KDM1A O60341 2/20 0.35
PYCR1 P32322 1/20 0.34
SLC6A2 P23975 1/20 0.34
SLC6A4 P31645 1/20 0.34
ATP4A P20648 1/20 0.33
ATP4B P51164 1/20 0.33
KDM4E B2RXH2 1/20 0.33
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
ATM Q13315 1/20 0.33
NISCH Q9Y2I1 1/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16201183 0.88 PRMT1 (0.50) PRMT6PRMT8PRMT1PRMT3CARM1
SCHEMBL16201353 0.88 ALDH1A1 (0.35) SLC6A2SLC6A4KDM4ENISCHKIF11
SCHEMBL16125843 0.87 PRMT6 (0.40) PRMT6PRMT8PRMT1PRMT3CARM1
SCHEMBL16201317 0.86 KDM4E (0.34) DRD2PYCR1KDM4E
SCHEMBL16204193 0.86 PRMT1 (0.53) PRMT6PRMT8PRMT1PRMT3CARM1
SCHEMBL16201342 0.85 PRMT1 (0.39) PRMT6PRMT8PRMT1PRMT3CARM1
SCHEMBL16201421 0.85 MEN1 (0.36) PRMT6PRMT8PRMT1PRMT3CARM1
SCHEMBL16772890 0.85 MAPK11 (0.38) KDM4E
SCHEMBL16201361 0.85 PRMT6 (0.45) PRMT6PRMT1SCN9ASLC6A2SLC6A4
SCHEMBL16201347 0.84 CRHR1 (0.38) PRMT1CARM1DRD2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9776972-B2 Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof EPIZYME INC. (US) 2017-10-03 US disclosed
US-9346761-B2 Arginine methyltransferase inhibitors and uses thereof Epizyme, Inc. (US) 2016-05-24 US disclosed
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2016-05-19 US disclosed
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF Epizyme, Inc. (US) 2014-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140323537-A1 ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT6 4/4885PRMT8 6/4885PRMT1 1/4885
US-20160137609-A1 PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF PRMT1, PRMT3, PRMT5 PRMT6 5/4885PRMT8 6/4885PRMT1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.